SCHEMBL1355825

SCHEMBL1355825

CCOP(=O)(Cc1ccc(Nc2ncc3cnn(-c4ccc(OC)cc4)c3n2)cc1)OCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 3/20 0.60
PTK2 Q05397 5/20 0.49
CDK4 P11802 2/20 0.48
CCND1 P24385 2/20 0.48
CCND2 P30279 2/20 0.48
CCND3 P30281 2/20 0.48
TBK1 Q9UHD2 1/20 0.47
BTK Q06187 2/20 0.44
NPY5R Q15761 1/20 0.43
FLT3 P36888 3/20 0.43
EGFR P00533 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
MAPK14 Q16539 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1356752 0.81 EIF2AK4 (0.61) EIF2AK4PTK2CDK4CCND1CCND2
SCHEMBL1355725 0.81 EIF2AK4 (0.64) EIF2AK4PTK2CDK4CCND1CCND2
SCHEMBL1355828 0.79 EIF2AK4 (0.59) EIF2AK4CDK4CCND1CCND2CCND3
SCHEMBL1356186 0.79 EIF2AK4 (0.67) EIF2AK4PTK2CDK4CCND1CCND2
SCHEMBL1356007 0.79 EIF2AK4 (0.67) EIF2AK4PTK2CDK4CCND1CCND2
SCHEMBL1355884 0.78 EIF2AK4 (0.60) EIF2AK4CDK4CCND1CCND2CCND3
SCHEMBL1356787 0.78 EIF2AK4 (0.60) EIF2AK4PTK2TBK1FLT3EGFR
SCHEMBL1356098 0.77 EIF2AK4 (0.62) EIF2AK4PTK2CDK4CCND1CCND2
SCHEMBL1355646 0.77 FLT3 (0.64) EIF2AK4CDK4CCND1CCND2CCND3
SCHEMBL1353786 0.77 EIF2AK4 (0.62) EIF2AK4PTK2CDK4CCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885PTK2 194/4885CDK4 101/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885PTK2 194/4885CDK4 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.